GlassScriptPhysician profile
William C Bingham
NPI 1750362497
$4,981.07
in general payments reported to CMS, 2019-2025
35 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $701 · 2020: $809 · 2021: $1,054 · 2022: $987 · 2023: $563 · 2024: $469 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $881.35 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $663.17 | 2021-2025 | Vraylar |
| Janssen Pharmaceuticals, INC | $610.44 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $355.02 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $299.82 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $229.34 | 2021-2025 | Trelegy Ellipta |
| Abbott Laboratories | $197.36 | 2021-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Takeda Pharmaceuticals U.S.A., INC. | $190.40 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $182.58 | 2019-2024 | Xifaxan, Trulance |
| Corium, LLC | $165.06 | 2023-2025 | Azstarys |
| Madrigal Pharmaceuticals | $148.43 | 2024 | Rezdiffra |
| Allergan, INC. | $143.93 | 2019-2020 | |
| Pfizer INC. | $124.62 | 2019-2023 | |
| Avanir Pharmaceuticals, INC. | $91.10 | 2019 | |
| Genzyme Corporation | $75.62 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $68.67 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $68.22 | 2020-2021 | |
| Genentech USA, INC. | $55.54 | 2019-2020 | |
| Esperion Therapeutics, INC. | $54.96 | 2020-2021 | |
| Otsuka America Pharmaceutical, INC. | $54.04 | 2022-2023 | Rexulti |
| Eisai INC. | $49.27 | 2020 | |
| Corcept Therapeutics | $47.27 | 2021 | |
| Daiichi Sankyo INC. | $33.88 | 2019 | |
| Almatica Pharma LLC | $28.20 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.51 | 2019 | |
| Exact Sciences Corporation | $18.92 | 2025 | The Cologuard Plus Collection Kit |
| Acadia Pharmaceuticals INC | $16.07 | 2025 | Daybue |
| Sonex Health, INC. | $15.47 | 2025 | Sx-One Microknife |
| Shire North American Group INC | $14.41 | 2019 | |
| Mylan Specialty L.P. | $14.26 | 2023 | Yupelri |
| Kowa Pharmaceuticals America, INC. | $12.66 | 2020 | |
| Neos Therapeutics, LP | $12.60 | 2022 | |
| Phathom Pharmaceuticals, INC. | $11.66 | 2025 | Voquezna |
| Supernus Pharmaceuticals, INC. | $11.42 | 2021 | |
| Sanofi-Aventis U.S. LLC | $10.80 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Bingham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.